The World Health Organization (WHO) provides an overview of alcohol consumption and its global impact. Alcohol, containing ethanol, is a psychoactive and toxic substance that can lead to dependence. In 2019, alcohol consumption was responsible for approximately 2.6 million deaths worldwide, with 1.6... million resulting from noncommunicable diseases, 700,000 from injuries, and 300,000 from communicable diseases. Men accounted for the majority of these deaths, totaling 2 million, compared to 600,000 among women. Additionally, an estimated 400 million people aged 15 and older were living with alcohol use disorders in 2019.
more
The article "Capacity-Building in Community-Based Drug Treatment Services" by Michael J. Cole focuses on the global challenges in providing adequate community-based drug treatment services. It highlights the gaps in availability, quality, and accessibility of evidence-based care. The article discuss...es the principles and strategies for capacity-building at three levels: individual, organizational, and service sector. It emphasizes using an empowerment model, engaging community stakeholders, and creating sustainable practices. The paper also addresses the need for systematic planning, assessment, and collaboration to strengthen drug treatment systems globally.
more
Trop. Med. Infect. Dis. 2022, 7, 152. https://doi.org/10.3390/tropicalmed7080152
The pamphlet "What is Addiction" explains addiction as a chronic, relapsing brain disease characterized by compulsive drug seeking and use, despite harmful consequences. It highlights the dangers of different drug categories, including sedatives, stimulants, and hallucinogens, and their potential he...alth and behavioral impacts. The document emphasizes the importance of combined medication and behavioral therapy in the treatment process, including detoxification, ongoing therapy, and relapse prevention. Additionally, it provides contact information for addiction treatment resources.
more
The pamphlet "ADHD Medications" provides an overview of medications commonly used to treat ADHD, such as Adderall, Vyvanse, and Ritalin. It explains that these medications do not enhance intelligence and affect individuals differently based on dosage and medical history. Potential dangers of misuse ...include insomnia, appetite changes, increased heart rate, and reliance on the drugs for studying. Combining ADHD medications with alcohol or sleeping pills is particularly dangerous. The pamphlet emphasizes the importance of proper medical supervision and provides resources for addiction support.
more
The pamphlet "Marijuana" explains the effects and risks of cannabis use. It describes THC, the psychoactive compound in cannabis, which binds to cannabinoid receptors in the brain, causing effects like relaxation, altered perception, and euphoria. Short-term effects include red eyes, hunger, and anx...iety, while long-term effects may involve memory loss, lung problems, and slowed brain development, especially with early and frequent use. It highlights the potential for negative impacts on mental and physical health while noting there are no direct deaths solely from marijuana use. The pamphlet provides links to resources for further information and recovery options.
more
The pamphlet "Prescription Benzodiazepines" explains the uses, effects, and risks of benzodiazepines, commonly prescribed for insomnia, anxiety, and panic attacks. It describes how these drugs enhance GABA activity to suppress brain activity, leading to short-term effects like drowsiness and anxiety... relief, but also potential long-term risks such as dependence, addiction, and withdrawal symptoms. The pamphlet highlights abuse methods, including combining benzodiazepines with other substances, which increases the risk of overdose, and emphasizes the importance of medical supervision for withdrawal management.
more
The pamphlet "Oxycodone" provides an overview of the opioid drug class, explaining its uses, effects, and risks. It describes positive effects like euphoria and pain relief, alongside negative effects such as respiratory depression, confusion, and constipation. Withdrawal symptoms include anxiety, i...ncreased pain sensitivity, and diarrhea. Treatment options include antagonist therapy (e.g., Naloxone) and substitution therapy (e.g., Methadone or Buprenorphine). The pamphlet emphasizes the importance of emergency care in cases of overdose and encourages seeking professional help for addiction or abuse.
more
The pamphlet "Methamphetamine" provides information about methamphetamine, an illegal stimulant with high abuse potential, though it has limited medical uses for conditions like ADHD and narcolepsy. It explains short-term effects such as appetite suppression, increased heart rate and blood pressure,... and seizures, as well as long-term effects like paranoia, depression, insomnia, and "meth mouth." It also outlines the legal consequences of possession and encourages seeking help for addiction through treatment resources.
more
The pamphlet "Alcohol and Depressants" explains the effects of depressants, including alcohol. Depressants slow brain activity by increasing the release of inhibitory neurotransmitters like GABA, leading to effects such as sedation, decreased anxiety, and reduced heart rate. Alcohol, a legal depress...ant, causes short-term effects like impaired judgment, vomiting, and blackouts, while long-term use can result in alcoholism, liver disease, strokes, and cancer. Alcohol withdrawal can be life-threatening, causing seizures and heart complications. The pamphlet emphasizes the importance of safe usage and provides resources for treatment and further information.
more
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more
The webpage by the National Institute on Drug Abuse (NIDA) discusses strategies for preventing drug misuse and addiction. It highlights the importance of early intervention, education, and support systems to reduce risk factors and strengthen protective factors. The content emphasizes the role of fa...milies, schools, and communities in promoting healthy behaviors and minimizing the likelihood of substance abuse, offering evidence-based prevention programs and practical tips.
more
Infection and Drug Resistance 2020:13 4047–4060
Launch of the WHO Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Key findings
Shown in blue is the estimated annual number of deaths attributed to drug use. Shown in red is theestimated annual number of deaths from drug use disorders. The difference between them is that theyrelate to indirect and direct causes of death, respectively.
The report provides an overview of alcohol consumption, related health harm, and policy responses in 30 European countries (EU Member States, Norway, and Switzerland). It highlights the high levels of alcohol consumption in the WHO European Region, which contribute to a significant disease burden co...mpared to other regions. The report covers trends in alcohol consumption and harm between 2010 and 2016, noting some progress in reducing alcohol-attributable mortality but stagnation in consumption reduction and heavy episodic drinking.
The assessment of alcohol policies shows variability in implementation across countries, particularly in areas like pricing and reducing the negative consequences of drinking. It emphasizes the need for stronger evidence-based policies, such as better regulation, taxation, and accessibility restrictions, to further reduce alcohol-related harm and achieve health-related Sustainable Development Goals.
more
Estimated annual number of deaths from drug use disorders, by type of drug.
Estimated annual number of deaths from drug use disorders per 100,000 people.
EXPERT OPINION ON DRUG SAFETY 2018, VOL. 17, NO. 11, 1129–1144.
Malaria during and after pregnancy contributes significantly to maternal mortality and adverse fetal outcomes. While effective and safe antimalarial treatments are essential, quinine — an older, less effective drug — has long bee...n favoured due to the limited safety data available on newer drugs. This review summarises the results of human studies investigating the safety and efficacy of antimalarial drugs during pregnancy and lactation.
more
Cardiovascular diseases (CVD) represent the highest burden of disease globally. Medicines are a critical intervention used to prevent and treat CVD. This review describes access to medication for CVD from a health system perspective and strategies that have been used to promote access, including pro...viding medicines at lower cost, improving medication supply, ensuring medicine quality, promoting appropriate use, and managing intellectual property issues. Using key evidence in published and gray literature and systematic reviews, we summarize advances in access to cardiovascular medicines using the 5 health system dimensions of access: availability, affordability, accessibility, acceptability, and quality of medicines. There are multiple barriers to access of CVD medicines, particularly in low- and middle-income countries. Low availability of CVD medicines has been reported in public and private healthcare facilities. When patients lack insurance and pay out of pocket to purchase medicines, medicines can be unaffordable. Accessibility and acceptability are low for medicines used in secondary prevention; increasing use is positively related to country income. Fixed-dose combinations have shown a positive effect on adherence and intermediate outcome measures such as blood pressure and cholesterol. We have a new opportunity to improve access to CVD medicines by using strategies such as efficient procurement of low-cost, quality-assured generic medicines, development of fixed-dose combination medicines, and promotion of adherence through insurance schemes that waive copayment for long-term medications. Monitoring progress at all levels, institutional, regional, national, and international, is vital to identifying gaps in access and implementing adequate policies.
more